Core Insights - The American Century U.S. Quality Growth ETF (QGRO) has made significant adjustments to its holdings, reflecting the flexibility of ETF managers in response to market movements [1][3][6] Fund Overview - QGRO was launched in September 2018 and charges 29 basis points for investing in U.S. firms with high growth potential and strong fundamentals [2] - The fund tracks the American Century U.S. Quality Growth Index, which screens for factors like income and quality using metrics such as cash flow and profitability [2] Recent Changes in Holdings - Notable changes in QGRO's portfolio include the dropping of at least two stocks and the addition of two new stocks, along with adjustments to the weights of six existing stocks [3] - Major tech companies such as Alphabet (GOOGL), Meta Platforms (META), and Amazon (AMZN) saw their weights decrease by 1.22%, 1.32%, and 1.74% respectively between November 21 and 24 [3] - Conversely, Amphenol Corporation (APH), Ralph Lauren Corporation (RL), and Expedia Group, Inc. (EXPE) experienced weight increases of 3.53%, 2.1%, and 1.33% respectively [4] Specific Stock Adjustments - The two stocks that were dropped from QGRO included Itron Inc. (ITRI) and Booz Allen Hamilton Holding Corporation (BAH), which had weights of 0.76% and 0.72% respectively before being removed [5] - The largest additions to the fund were Cardinal Health, Inc. (CAH) and HCA Healthcare, Inc. (HCA), with weights of 1.08% and 1.25% respectively [5] Performance Metrics - QGRO has achieved a year-to-date return of 12.4%, focusing on quality and growth-oriented companies [6] - The recent reduction in weight for three major tech stocks may attract investors looking to diversify into other rising companies [6]

Core Viewpoint - Aurinia Pharmaceuticals (AUPH) is currently outperforming its peers in the Medical sector, with a year-to-date return of 74.6% compared to the sector average of 6.3% [4]. Company Performance - Aurinia Pharmaceuticals is ranked 4 in the Zacks Sector Rank among 949 companies in the Medical group [2]. - The Zacks Rank for AUPH is 2 (Buy), indicating a positive earnings outlook [3]. - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% in the past quarter, reflecting stronger analyst sentiment [4]. Industry Context - AUPH is part of the Medical - Drugs industry, which consists of 144 companies and is currently ranked 75 in the Zacks Industry Rank [6]. - The average return for stocks in the Medical - Drugs industry this year is 6.1%, indicating that AUPH is performing significantly better [6]. - Another outperforming stock in the Medical sector is Cardinal Health (CAH), which has a year-to-date return of 77.1% and a Zacks Rank of 2 (Buy) [5].

Core Insights - Cardinal Health (CAH) shares have increased by 29.4% over the past month, reaching a new 52-week high of $210.33, and have gained 77.1% since the start of the year, outperforming the Zacks Medical sector and the Zacks Medical - Dental Supplies industry [1] Financial Performance - Cardinal Health has consistently beaten earnings estimates, reporting EPS of $2.55 against a consensus estimate of $2.21 in its last earnings report on October 30, 2025, and exceeding revenue estimates by 8.39% [2] - For the current fiscal year, Cardinal is projected to achieve earnings of $9.86 per share on revenues of $258.58 billion, reflecting a 19.66% increase in EPS and a 16.18% increase in revenues. For the next fiscal year, earnings are expected to rise to $10.9 per share on revenues of $277.02 billion, indicating year-over-year changes of 10.53% and 7.13%, respectively [3] Valuation Metrics - Cardinal Health has a Value Score of A, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of A, indicating strong potential for value investors [6] - The stock trades at 21.3 times current fiscal year EPS estimates, above the peer industry average of 15 times, and at 18 times trailing cash flow compared to a peer average of 12 times. The PEG ratio stands at 1.52, placing Cardinal in the top tier of stocks from a value perspective [7] Zacks Rank - Cardinal Health holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, making it a suitable choice for investors looking for stocks with strong potential [8] Industry Comparison - The Medical - Dental Supplies industry is performing well, ranking in the top 22% of all industries, providing favorable conditions for both Cardinal Health and its peer, McKesson Corporation (MCK), which also has a Zacks Rank of 2 (Buy) [11]

Core Insights - Wall Street experienced a rebound on November 21, 2025, with all three major stock indices rising nearly 1% due to investor optimism about a potential rate cut in December following dovish comments from John Williams, president of the Federal Reserve Bank of New York [1] Market Conditions - Despite the rebound, concerns over overvalued AI stocks persist, which could lead to a sell-off in the broader market at any time [2] Investment Strategy - In the current unstable environment, equity investors are advised to avoid high-priced stocks and consider dividend-growth stocks, as these companies typically exhibit strong financial health and provide a defensive hedge against economic uncertainty [3][5] - Dividend-growth stocks are characterized by a history of increasing dividends, which offers downside protection and potential for capital appreciation [5][6] Selected Dividend Growth Stocks - Five dividend growth stocks identified as solid choices include: - **Cardinal Health (CAH)**: Expected fiscal 2026 revenue growth of 16.2%, long-term earnings growth rate of 13.9%, and an annual dividend yield of 0.98% [12][13] - **Barrick Mining (B)**: Projected 2025 revenue growth of 21.5%, long-term earnings growth rate of 38.4%, and an annual dividend yield of 1.64% [14] - **NetEase (NTES)**: Anticipated 2025 revenue growth of 10.4%, long-term earnings growth rate of 9.9%, and an annual dividend yield of 1.70% [15] - **Lam Research (LRCX)**: Expected fiscal 2026 revenue growth of 14.1%, long-term earnings growth rate of 20.3%, and an annual dividend yield of 0.73% [16] - **Enersys (ENS)**: Projected fiscal 2026 revenue growth of 4%, long-term earnings growth rate of 15%, and an annual dividend yield of 0.76% [17] Selection Criteria - The selection of these stocks is based on criteria such as multi-year growth in dividends, sales, earnings per share (EPS), and undervaluation metrics [10][11] - Stocks selected have shown historical growth in dividends, sales, and EPS, indicating strong fundamentals and potential for sustained dividend payments [8][9]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks based on financial ratios [3] - Growth Score assesses a company's future earnings and financial health to identify sustainable growth opportunities [4] - Momentum Score capitalizes on price trends and earnings outlook changes to identify favorable buying opportunities [5] - VGM Score combines the three styles to highlight stocks with the best overall potential [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically delivered an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Company Spotlight: Cardinal Health (CAH) - Cardinal Health is a major player in healthcare services, serving nearly 90% of U.S. hospitals and managing over 43,000 pharmaceutical shipments daily [12] - The company operates in various segments, including Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution [12] - Cardinal Health holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong growth potential [13] - The company is projected to achieve year-over-year earnings growth of 18.9% for the current fiscal year, with upward revisions in earnings estimates [13][14]

Group 1: Cardinal Health - Cardinal Health's share prices have surged nearly 74% year to date, with significant gains following a strong quarterly earnings report [3][4] - Fiscal first-quarter 2026 revenue reached $64 billion, a 22% increase from the previous year, exceeding analyst expectations [3][5] - Adjusted earnings per share (EPS) of $2.55 surpassed Wall Street's forecasts, with estimates predicting EPS growth of 19% and 12.6% for the current and next fiscal years, respectively [5] Group 2: Loews - Loews shares have increased by 24% year to date, reflecting a turnaround from weak returns in the 2010s [6][8] - The company, controlled by the Tisch family, focuses on increasing intrinsic value per share and is actively repurchasing shares [9] - Loews owns significant stakes in CNA Financial and has interests in energy pipelines, hotels, and packaging, making it an attractive option for conservative investors seeking steady returns [8][9] Group 3: SanDisk - SanDisk's shares have surged over sixfold since splitting from Western Digital in February, with a 70% increase in the past month [10][11] - The company benefits from a NAND shortage, with robust demand for memory chips driven by artificial intelligence infrastructure [10] - SanDisk has raised NAND flash contract prices by 50%, and the market currently values its shares at a forward price-to-earnings (P/E) ratio of around 19, indicating potential for continued growth [10][12]

Core Viewpoint - A rotation in investor interest is occurring, moving from high-flying tech stocks to undervalued healthcare stocks, driven by strong earnings and emerging uptrends in the healthcare sector [1]. Group 1: Healthcare Sector Overview - The healthcare sector is experiencing a surge, with several stocks showing strong momentum and favorable rankings on Benzinga's Momentum scores [2]. - Investors are increasingly favoring healthcare stocks due to their strong earnings performance and technical indicators suggesting upward trends [1]. Group 2: Cardinal Health Inc. - Cardinal Health (NYSE:CAH) has a market cap of $48 billion and has consistently generated over $50 billion in sales each quarter since Q1 2023, primarily from generic and branded drug sales [4]. - The stock has increased over 70% year-to-date, with a significant 15% jump following a Q3 earnings report that exceeded consensus expectations by more than 16% [6]. Group 3: Guardant Health Inc. - Guardant Health (NASDAQ:GH) specializes in oncology diagnostics and reported a record revenue of $265 million, reflecting over 38% year-over-year growth [9]. - The stock has shown strong momentum, with a significant increase following better-than-expected earnings results [9]. Group 4: Abivax SA - Abivax (NASDAQ:ABVX) focuses on chronic inflammatory diseases and has seen its stock rise nearly 600% in a single session following positive Phase 3 clinical trial results [10]. - The stock has continued to rise, with a 60% increase over the last three months and a consensus Buy rating from analysts [12]. Group 5: Medpace Holdings Inc. - Medpace (NASDAQ:MEDP) provides clinical trial services and has experienced a stock increase of over 75% year-to-date, driven by strong earnings performance [13]. - The company reported Q3 revenue growth of more than 23% year-over-year, exceeding expectations and indicating strong future prospects [15]. Group 6: Elanco Animal Health Inc. - Elanco Animal Health (NYSE:ELAN) develops healthcare products for pets and farm animals, with shares up 76% this year due to solid earnings [16]. - The company raised its full-year guidance following strong sales growth in both its Pet Health and Farm Animal divisions [18]. Group 7: GeneDx Holdings Corp. - GeneDx Holdings (NASDAQ:WGS) specializes in exome and genome testing and has recently turned a profit, with a market cap approaching $4 billion [19]. - The company has raised guidance for total revenue and adjusted gross margins, indicating strong growth potential [19].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Cardinal Health (NYSE: CAH) 2025 Conference Summary Company Overview - **Company**: Cardinal Health - **Date**: November 11, 2025 - **Key Speakers**: Aaron Alt (CFO), Matt Sims (Head of IR) Key Points Financial Performance - Cardinal Health reported strong Q1 results with all five operating segments achieving double-digit profit growth, particularly in the pharma business, which saw a profit increase of 26% [2][3][4] - The company raised its adjusted EPS guidance to $9.65-$9.85, reflecting a year-over-year growth of 17%-20% [4][5] Business Segments - **Pharma Business**: Strong demand and execution, particularly in specialty distribution, contributed significantly to profit growth [2][3] - **Other Business**: The aggregation of smaller businesses (Nuclear Precision Health, At Home, OptiFreight Logistics) saw a profit growth of 60%, partly due to the acquisition of ADSG [3][4] - **Global Medical Products and Distribution (GMPD)**: Experienced revenue growth with the Cardinal Health brand business growing at 6% for two consecutive quarters [4][5][56] Customer Onboarding and Growth Strategy - Cardinal Health onboarded $10 billion in new business in the latter half of the previous year and is on track to onboard an additional $7 billion in the first half of the current year [5][12] - The company is focusing on investing in new customers and enhancing its MSO platforms to drive future growth [5][6] Market Dynamics and Demand - Demand across all segments exceeded expectations, with notable growth in generics and specialty products [9][10] - The company noted a consistent market dynamic, indicating no dislocation between buying and selling, which contributed to strong quarterly results [10][11] Specialty Business Focus - Cardinal Health emphasizes its strength in "otherologies" (rheumatology, urology, gastroenterology) rather than oncology, which is a key differentiator in its specialty business strategy [19][20] - The company aims to leverage its distribution capabilities and technology to enhance partnerships with healthcare providers in these specialty areas [25][26] Competitive Landscape - The medical products business is undergoing competitive changes, with Cardinal Health focusing on improving its GMPD segment to maintain market share against competitors like Medline and McKesson [56][59] - The company is actively seeking opportunities arising from industry transitions, such as acquisitions and partnerships, to enhance its competitive position [60] Operational Efficiency - Cardinal Health is investing in automation and optimizing its distribution network to improve operational efficiency and reduce costs [36][37] - The company is committed to maintaining high service levels while managing costs effectively [37][39] Future Outlook - The company anticipates continued growth in its nuclear precision health business, projecting a long-term profit growth of 10% [74][75] - Cardinal Health remains confident in its long-term guidance, citing its essential role in the American healthcare system and the ongoing demand for its services [49][50] COVID-19 Impact - COVID-19 was noted as a slight headwind in Q1, but overall demand growth offset this impact [78][79] - The company expects COVID-related profits to continue declining, with a focus on broader market dynamics moving forward [79][80] Conclusion Cardinal Health's strong financial performance, strategic focus on specialty and otherologies, and commitment to operational efficiency position the company well for future growth in a competitive healthcare landscape. The ongoing investments in customer onboarding and technology enhancements are expected to drive continued success.